Dr Alan I Freedman, MD | |
1011 Coves Pheasant Ct, Biltmore Lake, NC 28715-8934 | |
(561) 716-2939 | |
Not Available |
Full Name | Dr Alan I Freedman |
---|---|
Gender | Male |
Speciality | Urology |
Location | 1011 Coves Pheasant Ct, Biltmore Lake, North Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1174544779 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208800000X | Urology | 2007-00230 (North Carolina) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Alan I Freedman, MD 1011 Coves Pheasant Ct, Biltmore Lake, NC 28715-8934 Ph: (561) 716-2939 | Dr Alan I Freedman, MD 1011 Coves Pheasant Ct, Biltmore Lake, NC 28715-8934 Ph: (561) 716-2939 |
News Archive
Van Andel Research Institute (VARI) investigators working in collaboration with Cleveland Clinic researchers have determined that two types of kidney tumors previously thought to be different diseases are actually variations of the same disease.
A simple blood test capable of detecting trace levels of leukaemia cells remaining after intensive chemotherapy has been developed by scientists at the National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London.
A team of researchers from the Cleveland Clinic and Case Western Reserve School of Medicine have identified critical complex mechanisms involved in the metastasis of deadly "triple negative" breast cancers. These tumors are extremely difficult to treat, frequently return after remission, and are the most aggressive form of breast cancer in women. The discovery of this critical interaction of mechanisms could be used to develop new life saving treatments to kill metastatic tumors in TNBC.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the U.S. Food and Drug Administration has granted orphan drug designation to its gene therapy program for the treatment of hemophilia B.
› Verified 3 days ago